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MiR-146b negatively regulates 
migration and delays progression of 
T-cell acute lymphoblastic leukemia
Nádia C. Correia, Rita Fragoso, Tânia Carvalho, Francisco J. Enguita & João T. Barata
Previous results indicated that miR-146b-5p is downregulated by TAL1, a transcription factor critical 
for early hematopoiesis that is frequently overexpressed in T-cell acute lymphoblastic leukemia (T-ALL) 
where it has an oncogenic role. Here, we confirmed that miR-146b-5p expression is lower in TAL1-
positive patient samples than in other T-ALL cases. Furthermore, leukemia T-cells display decreased 
levels of miR-146b-5p as compared to normal T-cells, thymocytes and other hematopoietic progenitors. 
MiR-146b-5p silencing enhances the in vitro migration and invasion of T-ALL cells, associated with 
increased levels of filamentous actin and chemokinesis. In vivo, miR-146b overexpression in a TAL1-
positive cell line extends mouse survival in a xenotransplant model of human T-ALL. In contrast, 
knockdown of miR-146b-5p results in leukemia acceleration and decreased mouse overall survival, 
paralleled by faster tumor infiltration of the central nervous system. Our results suggest that miR-
146b-5p is a functionally relevant microRNA gene in the context of T-ALL, whose negative regulation 
by TAL1 and possibly other oncogenes contributes to disease progression by modulating leukemia cell 
motility and disease aggressiveness.
Improved therapy regimens have led to cure rates close to 80% in children with acute lymphoblastic leukemia 
(ALL)1,2. Although risk-adjusted chemotherapy improved the outcome of ALL patients presenting with T-cell 
phenotype (T-ALL), these still have higher risk for induction failure, early relapse, and isolated CNS relapse3. 
Thus, a better understanding of the biology of the disease, namely through the molecular analysis of com-
mon genetic and epigenetic alterations, is necessary to the development of more efficacious and less toxic 
rationally-designed therapies.
MicroRNAs (miRNAs) are small, non-coding RNAs that primarily function as endogenous translational 
repressors of protein-coding genes4. Importantly, miRNAs are key regulators of cancer progression5–7, namely 
by modulating the expression of oncogenes and tumor suppressors and thereby inhibiting or promoting tum-
origenesis. In ALL, microRNA expression signatures delineate leukemia subgroups8–11, and deregulated miRNA 
networks have been implicated in T-ALL12–16.
TAL1 is a transcription factor essential for the maintenance of hematopoietic stem cells and regulation of early 
hematopoiesis17–20. TAL1 expression is shut down upon T-cell lineage commitment21 and its aberrant expression 
in committed T-cell precursors is associated with leukemogenesis, with TAL1 overexpression occurring in more 
than 60% of T-ALL patients22–24. Although a considerable number of TAL1 downstream target genes have been 
identified to date12,23,25–36 validation and characterization of their functional involvement in TAL1-mediated leu-
kemogenesis remain fragmentary.
Recently, it has been demonstrated that TAL1 regulates the expression of microRNA genes37,38. Prominent 
amongst these is miR-223, which is positively regulated by TAL137,38 and highly expressed in T-ALL13. TAL1 tran-
scriptionally activates miR-223 and thereby downregulates the tumor suppressor FBXW738. However, whether 
other microRNAs are involved in TAL1-mediated T-cell oncogenesis has not been addressed. Several studies have 
implicated miR-146b-5p, which is inhibited by TAL137, as having a tumor suppressor role in solid tumors39–44 and 
in human diffuse large B-cell45 and mouse PTEN-deficient T-cell46 lymphomas. In the present study, we show that 
miR-146b-5p is a functionally relevant TAL1 downstream microRNA target gene, whose downregulation contrib-
utes to T-ALL by impacting on leukemia cell motility in vitro and disease aggressiveness in vivo.
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Results
MiR-146b is downregulated in T-ALL. We previously showed that miR-146b-5p was downregulated by 
TAL1 in T-ALL cell lines and that TAL1-positive T-ALL patients tended to display reduced levels of miR-146b-5p 
as compared to other T-ALL cases37. Using a recently published miRNA expression dataset47,48 we found that 
pediatric T-ALL patient samples overexpressing TAL1 (TAL subgroup) had significantly lower levels of miR-
146b-5p than samples carrying other genetic alterations (Fig. 1A). Furthermore, the knockdown of TAL1 in a 
T-ALL cell line resulted in marked up-regulation of pri-miR-146b (Fig. 1B), indicating a strong negative impact 
of TAL1 on miR-146b expression. Notably, we also found that T-ALL primary cells and cell lines expressed sig-
nificantly lower levels of miR-146b-5p than normal hematopoietic control cells, such as T-cells, thymocytes, bone 
marrow precursors and CD34+ hematopoietic progenitor/stem cells (Fig. 2). Overall, these observations led us 
to hypothesize that downregulation of miR-146b-5p is functionally relevant in the context of human T-ALL in 
general and especially in TAL1 overexpressing cases.
MiR-146b inhibits motility, migration and invasion of T-ALL cells. Next, we sought to determine 
the functional consequences of miR-146b decreased expression in T-ALL. To this end, we stably knocked down 
miR-146b-5p in TAL1-negative (DND-41 and MOLT-4) T-ALL cell lines or overexpressed miR-146b-5p in 
TAL1-positive (JURKAT and CEM) cells (Figure S1). We found no significant differences in cell proliferation, as 
assessed by cell counts (Figure S2A,B) and thymidine incorporation (Figure S2C), either in normal culture con-
ditions (10% FBS) or under serum starvation (0% FBS). This is in accordance with a previous study reporting that 
miR-146a/b enforced expression has no effects on the proliferation of KOPTK1, RPMI-8402, DND-41 or TALL-1 
cells16. Moreover, no differences were found in T-ALL cell viability upon modulation of miR-146b expression 
(Figure S3). Given that miRNA-146b-5p was shown to be highly up-regulated during the later stages of thymocyte 
maturation49, we reasoned that modulation of its expression could have an effect on T-ALL cell differentiation. 
However, we monitored the cell lines for several weeks and none displayed changes in the stage of maturation in 
which they were blocked (Figure S4).
Altered expression of miR-146b has been linked to the migration properties of cancer cells in solid 
tumors40,43,44,50. Thus, we next investigated the functional impact of miR-146b on the motility and migration of 
T-ALL cells. Using time-lapse microscopy, we found that overexpression of miR-146b in TAL1-positive cells 
resulted in decreased cell motility (Fig. 3A–C), suggesting that the miRNA negatively affects random cell move-
ment (chemokinesis). In addition, miR-146b reduced directional migration in response to serum, as assessed 
in transwell assays (Fig. 3D). On the contrary, downmodulation of miR-146b-5p in TAL1-negative T-ALL cells 
Figure 1. TAL1-positive T-ALL cells express low levels of miR-146b-5p and TAL1 silencing upregulates 
miR-146b-5p primary transcript. (A) miR-146b-5p expression in primary T-ALL cells. MiR-146b-5p levels 
were analyzed from publically available data48 in a cohort of 64 T-ALL patients comparing TAL1+ T-ALL 
cases (such as SIL-TAL, TCR-TAL and other TAL1+ cases – TAL1 subgroup) with T-ALL cases carrying other 
genetic abnormalities (TLX1, TLX3, HOXA and immature subgroups – Other T-ALLs). Statistical analysis was 
performed using Student’s t-test (* * * p < 0.001). (B) CEM cells were nucleofected with siRNAs against TAL1 
(siTAL1) or a non-targeting control (siNT) and the expression of TAL1 (left) or pri-miR-146b (right) transcript 
was assessed by qRT-PCR. Values indicate the mean ± lower and upper limit of three technical replicates 
relatively to the siNT control.
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promoted migration under the same conditions (Figs 3E and S5). Notably, overexpression of miR-146b-5p in 
TAL1-positive T-ALL cells decreased their invasion ability (Figs 3F and S5), whereas silencing of miR-146b-5p 
in TAL1-negative cells had the opposite effect (Fig. 3G), as determined by cell migration through a matrix layer. 
In agreement with the impact of miR-146b on T-ALL cell movement, miR-146b-5p silencing led to increased 
actin polymerization (Fig. 4A,B). On the contrary, T-ALL cells overexpressing miR-146b exhibited lower levels 
of polymerized actin (Fig. 4C,D).
MiR-146b delays leukemia progression in vivo. To investigate whether miR-146b exerts a tumor 
suppressor-like role in vivo, we used murine xenograft models of human T-ALL51. We transplanted MOLT-4 
cells with stable silencing of miR-146b-5p or mock vector into immunocompromised mice. Silencing of miR-
146b-5p in T-ALL cells significantly accelerated leukemia-associated death of transplanted mice (Fig. 5A). In 
contrast, miR-146b overexpression in CEM T-ALL cells delayed leukemia-associated death of transplanted mice 
(Fig. 5B), which presented decreased extent of infiltration of secondary organs (other than bone marrow) as 
compared to controls (Figs 5C–E and S6). For instance, a minimal infiltration pattern, with isolated cells, was 
observed for CEM cells with miR-146b overexpression, while empty vector-transduced cells showed a tendency 
towards the formation of larger foci of 5–10 cells (Fig. 5D). T-ALL cells overexpressing miR-146b also orig-
inated less severe leptomeningeal infiltration than control cells (Figs 5E and S6). Moreover, the frequency of 
leukemic cells in the blood reflected the pattern of leukemia spread, with a clearly lower percentage in the case 
of miR-146b-overexpressing cells (Fig. 5C). Altogether, these findings are consistent with the negative effect on 
motility we observed for miR-146b in vitro and with a tumor suppressor role for miR-146b-5p in T-ALL.
Discussion
The identification and characterization of the full spectrum of TAL1-regulated genes, including microRNA genes, 
with functional impact on leukemia development has the potential to reveal novel molecular targets for ther-
apeutic intervention. We previously showed that miR-146b-5p is negatively regulated by TAL137. In the pres-
ent study, we demonstrated that miR-146b-5p downmodulates motility, migration and invasion of T-ALL cells 
in vitro and leukemia dissemination and disease progression in vivo. Loss of miR-146a (which differs from miR-
146b-5p by two nucleotides) in fetal liver hematopoietic progenitors overexpressing activated Notch does not 
appear to impact tumor onset in a mouse model of Notch-induced T-ALL16. Consequently, miR-146a/b have been 
discarded from a list of candidate tumor suppressor microRNAs in T-ALL. However, the inability of miR-146a to 
prevent leukemogenesis might be due to redundancy with miR-146b-5p, which is very abundant in hematopoi-
etic progenitor cells. Alternatively, since miR-146a and miR-146b can also have specific, non-redundant targets 
and functions46, one cannot exclude that miR-146b may have a tumor suppressor role in human T-cells that is 
not embraced by miR-146a. Finally, it is plausible that miR-146a may be insufficient to prevent the activity of a 
very strong oncogene such as intracellular Notch. Nonetheless, in both our xenograft T-ALL models miR-146b 
modulation is sufficient to affect T-ALL development.
Figure 2. T-ALL cells express lower levels of miR-146b-5p than normal controls. (A,B) MiR-146b-5p 
expression in primary T-ALL samples was analyzed from publicly available data (GSE51908 and ref 10).  
(A) MiRNA expression in T-ALL patients and cell lines was compared to normal T-cells or CD34+ 
hematopoietic progenitor/stem cells (HSCP) cells from the peripheral blood of healthy donors. Data was 
collected from the GEO database (GSE51908). (B) MiRNA expression in T-ALL patients was compared to 
thymocytes, bone marrow (nBM) and CD34+ peripheral blood cells of pediatric samples10. Statistical analysis 
was performed using One-way ANOVA (* p < 0.05; * * * * p < 0.0001).
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Figure 3. MiR-146b downregulates cell motility, migration and invasion of T-ALL cells. CEM cells 
ectopically expressing miR-146b (146b OE) or mock-transduced (Empty) were compared; MOLT-4 cells 
with downregulation of miR-146b-5p (146b KD) or scramble-transduced (SCR) were compared. Statistical 
significance was calculated using paired two-tailed Student’s t-test (* p < 0.05; * * p < 0.01; * * * p < 0.001).  
(A) Migration of individual CEM cells (n = 20) was recorded for 30 min by time-lapse video microscopy. The 
flower plot diagrams are representative of ten independent experiments. The starting point of each track is 
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MiR-146b-5p is amongst the most expressed miRNAs in mature single-positive thymocytes49, being 
up-regulated during the double-positive to single-positive thymocyte transition37, consistent with a model 
whereby TAL1 aberrant expression contributes to leukemogenesis in developing thymocytes in part by 
downregulating miR-146b-5p. Nonetheless, our demonstration that T-ALL cells, irrespectively of their TAL1 
status, express significantly lower levels of miR-146b-5p than healthy controls suggests that miR-146b-5p may be 
modulated by other factors in addition to TAL1. Identifying those factors may contribute to the growing under-
standing of the oncogenic pathways that underlie T-ALL and thus deserves further investigation.
Our demonstration that miR-146b-5p alters the motility, migration and invasion capacities of T-ALL cell 
lines in vitro is in agreement with previous findings in solid tumors40,43,44,50, including osteosarcoma (via AUF1 
regulation)39, breast cancer40 (via NF-κ B regulation)41, glioma (via MMP1642 and EGFR43 regulation), and pan-
creatic cancer (via MMP16 regulation)44. Evidently, our findings using leukemia cell lines warrant investigation in 
patient cells. Moreover, the question arises of which miR-146b-5p target(s) may be responsible for the effects we 
observed in T-ALL cells. Previously, we showed that miR-146b-5p validated targets are enriched in genes involved 
in biological processes such as inflammation (e.g., NF-kB and IL1/IL1R signaling pathways) and cancer37. Our 
current analyses, using GeneCodis52, extended to miR-146b-5p predicted target genes (n = 250, Table S1) and 
indicated that several migration-related processes are significantly enriched, including axon guidance, neural 
crest cell migration or regulation of actin cytoskeleton reorganization (Figure S7). In agreement, functional anno-
tation analysis, using DAVID53, returned several gene ontology terms related to cell motility and migration that 
are significantly associated (p < 0.05) with miR-146b-5p predicted targets genes (Table S2). In particular, 50 out 
of 250 genes are implicated in biological processes such as cytoskeleton, cell migration, actin filament-based pro-
cesses, and cell projections (Table S3). Thus, our bioinformatics analyses suggest that miR-146b-5p likely regulates 
cell motility and migration via multiple target genes.
Our in vivo findings suggest that miR-146b impacts the capacity of T-ALL cells to infiltrate hematopoietic 
and non-hematopoietic organs, thereby delaying leukemia progression and effectively acting as a tumor sup-
pressor gene. MiR-146b has been implicated also in preventing proliferation of PTEN-deficient mouse CD4 
thymocytes46 and human diffuse large B-cell lymphoma cells45. Moreover, several reports41,46,54,55 implicate miR-
146b in decreasing NF-κ B pathway activation in inflammation and cancer. In particular, miR-146b-5p has an 
anti-oncogenic function in the context of PTEN-deficient T-cell leukemia in mice that is mediated by attenuation 
of TCR signaling through direct repression of TRAF6. The consequence is inhibition of downstream NF-κ B acti-
vation and c-Myc induction, associated with reduced proliferation46. However, our data suggest that miR-146b-5p 
does not have a similar role on proliferation of human T-ALL cells. In accordance, preliminary evaluation of 
NF-κ B activation by assessment of the phosphorylation of IkBα and of RelA in our transduced T-ALL cell lines 
did not reveal any obvious differences modulated by miR-146b (data not shown). In addition, our studies using 
Ki-67 suggest that miR-146b-5p does not significantly affect human T-ALL cell proliferation in vivo (not shown). 
Although we cannot exclude the possibility that miR-146b-5p impacts leukemia cell survival in vivo, such an 
effect could still be the result of altered migration, which was shown to affect T-ALL cell viability in the bone 
marrow by regulating niche localization56–58.
From a therapeutic standpoint, it is noteworthy that intra-tumor injection of exosomes derived from 
miR-146b-expressing mesenchymal marrow stromal cells was shown to reduce glioma xenograft growth in a rat 
model of primary brain tumor59. Modulation of miR-146b appears to clearly affect CNS infiltration in our in vivo 
models of human T-ALL. In this context, it would be interesting to determine whether plasma levels of miR-146b 
in T-ALL patients correlate with CNS infiltration, and whether this could be transversal to other acute leuke-
mias. Strategies involving carrier-based nanotechnology to enrich or antagonize miRNAs have been successfully 
experimented in murine lymphoma models60. When will these translate into clinical applications can only be 
speculated, but it is tempting to envisage future administration of miR-146b as a potential means to prevent or 
decrease CNS involvement, which is a major risk factor in T-ALL. In summary, we showed that miR-146b-5p 
downregulation promotes T-ALL by modulating leukemia cell motility, invasion, organ dissemination and con-
sequent disease aggressiveness. These observations reveal a player in T-ALL biology and may help defining new 
therapeutic options in this malignancy.
Methods
For detailed experimental procedures see online Supplemental Methods.
Cell lines. Human T-ALL cell lines were maintained in RPMI medium (GIBCO) supplemented with 10% FBS 
at 37 °C with 5% CO2 and split every 2–3 days.
placed at the axis origin. (B) Migration velocity (top) and accumulated traveled distance (bottom) of leukemic 
cells depicted in (A). Lines indicate mean values. (C) The mean velocity (top) and accumulated distance 
(bottom) of 20 individual leukemic cells was assessed in ten independent time-lapse experiments. The bar 
graphs represent the mean ± SD. (D–G) Migration (D,E) and invasion (F,G) were assessed through transwell 
and matrigel coated transwell assays, respectively. Serum was used as chemoattractant. Cells were plated on 
the upper chamber of the transwell in culture medium in the absence (R0) or presence of 10% serum (R10), as 
indicated: medium present in the upper chamber > medium in the lower chamber (R10). The number of cells 
was determined by counting five non-overlapping high-power fields (HPF×100) per transwell. At least three 
independent experiments were performed (in triplicate). Graphs represent mean ± SD number of cells per HPF 
counted in at least three independent migration experiments.
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Transduction of T-ALL cells for miR-146b overexpression or knockdown. VSVG-pseudotyped 
lentiviruses were produced by transient three-plasmid co-transfection into 293T cells. The vectors for miR-146b 
overexpression and respective control (pLemiR-146b-OE and pLemiR-empty) were kindly provided by the Sai 
Yendamuri lab. Both mature forms of miR-146b are expressed (miR-146b-5p and miR-146b-3p)50. The lentiviral 
vector for miR-146b-5p inhibition (146b_KD) is the pEZX-AM03 vector (Tebu-bio) and expresses the specific 
miRNA inhibitor against hsa- miR-145b- 5p. The resulting cell lines expressing the vectors or the corresponding 
mock control were sorted for equivalent RFP expression.
Assessment of proliferation. T-ALL cell lines were plated (5 × 105 cells/mL) in triplicates in flat-bottom 
96-well plates at 37 °C with 5% CO2 on day zero, either in RMPI-10 or RPMI-0 (no serum). Proliferation was 
measured at the indicated time points either by 3H-thymidine incorporation or by cell counts using a hemocytom-
eter and trypan-blue for dead cell exclusion. Every other day, cells were counted and seeded as 5 × 105 cells/mL.
Figure 4. MiR-146b downmodulates actin polymerization in T-ALL cells. (A,C) Representative confocal 
images used for quantification of polymerized actin (F-Actin) through phalloidin-488 fluorescence intensity. 
The fluorescence of MOLT-4 cells (n = 30–50) with miR-146b-5p downregulation (A,B) or CEM cells with 
miR-146b overexpression (C,D) and respective controls was quantified in high-magnification (× 63 objective) 
images. Scale bar: 10 μ m. (B,D) The mean intensity of fluorescence per area was quantified in independent 
immunofluorescence staining preparations. The bar graphs depict the mean ± SD of 6 (MOLT-4) or 5 (CEM) 
independent experiments. The statistical significance of the differences observed was calculated using paired 
two-tailed Student’s t-test (* * p < 0.01). The numeric values above each graph denote the average fold difference 
of F-actin per cell area in experimental conditions over those of control cells.
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Figure 5. In vivo miR-146b-5p behaves as a tumor suppressor, with significant impact on T-ALL 
disease progression. NOD/SCID mice were xenotransplanted either with MOLT-4 cells with miR-146b-5p 
downregulation (146b KD; red) versus scramble transduced cells (SCR; grey) or with CEM cells ectopically 
expressing miR-146b (146b OE; blue) versus empty vector-transduced cells (Empty; grey). (A,B) Kaplan-Meyer 
survival curves, with a median survival of (A) 47 days for 146b KD (n = 5) versus 55 days for SCR control 
(n = 5), and (B) of 36 days for 146b OE (n = 5) versus 32 days Empty control (n = 5) (p < 0.05 in both cases, 
log-rank test). (C–E) Leukemia infiltration into different organs was assessed in CEM-transplanted mice (n = 4 
Empty; n = 4 146b OE) at day 25 post-injection. (C) Erythrocyte-free cell suspensions of each organ were 
analyzed by flow cytometry to detect the presence of leukemic (RFP+ ) cells. The lines indicate the average 
percentage. BM – Bone marrow. (D) Representative micrographs of the bone marrow, spleen, liver and soft 
tissue. Immunohistochemistry for human vimentin was used to identify minimal infiltration by leukemia cells. 
Infiltration in the soft tissue originated from direct invasion from the bone marrow through the bone foramina 
of vertebra (* ), skull, mandibular bones. 3,3′ -Diaminobenzidine counterstained with hematoxylin; size units in 
μ m; original magnification 200× (bone marrow and soft tissue), 100× (liver and spleen). (E) Representative  
H&E micrographs of CNS – brain (olfactory bulb) and cerebellum. In both experimental groups CNS 
infiltration corresponded to leptomeningeal infiltration, with the formation of multifocal to diffuse solid tumor 
masses (* ) and with decreased severity in CEM 146b OE mice in comparison with controls. Size units in μ m; 
original magnification 25× (brain) and 50× (cerebellum).
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Assessment of cell viability. Cell viability was determined by flow cytometry analysis of Forward Scatter 
versus Side Scatter (FSCxSSC) distribution in an LSRFortessa cell analyzer (BD Biosciences).
Cell migration and invasion assays. Cells (105) were seeded in a 5μ m pore transwell insert (Millipore) in 
RPMI medium either in the absence (R0) or presence of 10% serum (R10) and plated in a 24-well plate. Serum 
was added to the bottom chamber as a chemoattractant. For invasion assays, the transwell inserts were coated 
with a layer of Matrigel Growth Factor Reduced Matrix (BD biosciences).
Immunofluorescence and time-lapse confocal microscopy. Distribution of F-actin was assessed 
using Alexa Fluor 488-phalloidin (Thermo Fisher). ICY software was used for 3D image reconstruction and 
fluorescence quantification of 30–50 cells per sample. For time-lapse video assessment of cell movements, 
phase-contract images were obtained every 60 s for 30 min at 37 °C with 5% CO2. Velocities and accumulated dis-
tance of 20 randomly selected leukemic cells were determined by manually tracking individual cells using manual 
tracking plugin on ImageJ (NIH) software.
Human T-ALL in vivo. Age-matched (8 to 14 weeks) NOD/SCID mice were xenotransplanted with 
T-ALL cell lines and equally distributed by the experimental groups (n = 4 or 5 mice per group, as indicated). 
Experiments were performed once. Leukemia cells (107) were injected in the tail vein. Experimental procedures 
were approved by the institutional Animal Ethics Committee from Instituto de Medicina Molecular and followed 
the recommendations for the care and use of laboratory animals from the European Commission and Portuguese 
authorities.
Statistical analysis. All analyses were performed using GraphPad Prism version 6.01 (GraphPad Software). 
Significance was set for p < 0.05 (* p < 0.05; * * p < 0.01; * * * p < 0.001: * * * * p < 0.001).
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